VanEck JP Morgan EM Local Currency Bond ETF vs Zoetis Inc — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $25.6, while Zoetis Inc trades at $73.69 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none, and VanEck JP Morgan EM Local Currency Bond ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| EMLC | ZTS | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $26.59 | $156.76 |
52-Week Low | $24.83 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $25.615, showing minimal daily movement with a slight decline of 0.02%. Technical indicators signal a bullish trend with strong moving average support, while oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payments of $0.13-$0.14 per share. Emerging market debt exposure provides yield advantages over developed markets, though volatility remains a consideration.
The outlook for EMLC appears favorable given the Federal Reserve's accommodative stance and emerging market yield premiums. Key opportunities include attractive fixed income returns compared to Treasury bonds, while risks center on emerging market volatility and inflation concerns. The technical bullish signal supports near-term price stability with potential for gradual appreciation.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Trailing returns across standard periods
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →